TG Therapeutics, Inc.

TGTX Healthcare Biotechnology

TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.

Revenue
+70.3%
EPS
−73.7%
Free cash flow
+427.1%
Total debt
+204.2%

Quarter to June 2026, against a year earlier

60.07 2.09 +3.60%
Market cap
$8.9B
P/E
19.1×
Fwd P/E
62.4×
Dividend yield
—
F-score
5/9
Altman Z
6.29
Beneish M
0.80
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

111.96% 102.75% 112.60% 100.28%
Piotroski F-Score
4 4 4 5
ROA
55.55% 54.50% 42.27% 37.70%
ROIC
8.91% 10.25% 11.48% 10.69%
Return on Tangible Assets
101.02% 93.75% 51.33% 50.33%
Average Days of Receivables
182.11 181.01 204.32 183.32
Free Cash Flow per Share
(0.48) (0.17) (0.10) 0.12
Free Cash Flow
(70.24) (24.99) (14.19) 17.39
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026